Health and Healthcare
Amgen (AMGN) And Johnson & Johnson (JNJ): When The Patients Die
Published:
Two of the best-selling drugs in the US are Procrit from Johnson & Johnson (NYSE: JNJ) and Aranesp from Amgen (NASDAQ:AMGN). The products treat anemia in patients with kidney dialysis issues.
Studies now show that the drugs can cause death in cancer patients either from clots or an increased rate of growth in tumors. Concerns about the drugs are not new. According to The New York Times "Sales of Aranesp, Amgen’s best-selling product, declined to $3.6 billion last year from $4.1 billion in 2006."
It is not surprising that the companies defend the use of the drugs as being relatively safe. but it is possible that the side effects have been known by both firms for some time. They did create the products and test them extensively before submitting them to the FDA.
The new battle between the FDA and its scientists on the one hand and the pharma firms on the other is a repeat of a pattern that is now decades old. It puts the rights of patients against the right of the companies to make money. Ultimately, it puts the value of the stocks which shareholders hold at risk. By risking some liability, the firms have not done them any favors.
Douglas A. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
